Drug Pipeline

AZD0120 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
11
Active Studies
10
Recruiting
1
Phase 3
5
Top Sponsors
3
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-12 NCT07391657
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA)…
Trial sites expanded: 111 -> 116 locations
2026-06-10 NCT06530849
A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus
overall status: "Recruiting" → "Active Not Recruiting"
2026-06-10 NCT06530849
A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus
Enrollment reduced: 118 -> 20 participants
Active Studies by Phase
Phase 3
1
Phase 1/2
5
Phase 1
3
Early Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07391657 A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA)… Relapsed Refractory Multiple Myeloma Recruiting
Phase 1/2
NCT06235229 A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma Multiple Myeloma Recruiting
NCT07081646 A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With… Relapsed AL Amyloidosis Recruiting
NCT05850234 AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1) Relapsed/Refractory Multiple Myeloma Recruiting
NCT06897930 A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With… Lupus Erythematosus, Systemic Recruiting
NCT06530849 A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus Refractory Systemic Lupus Erythematosus Active, Not Recruiting
Phase 1
NCT07250269 Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With… Relapsed/Refractory AL Amyloidosis Recruiting
NCT07073547 A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular… Multiple Myeloma Recruiting
NCT07295847 A Study of AZD0120 in Autoimmune Diseases Systemic Sclerosis Recruiting
Early Phase 1
NCT07350837 CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants Highly Sensitized Patients Awaiting Kidney Transplant Recruiting
NCT05858684 Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE)… CAR-T Cell Therapy Recruiting
Sponsors Running AZD0120 Trials
Disease Areas
Get alerts when AZD0120 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free